Cdx2 is a homeobox gene that has been shown to play a role in the development of the small and large intestine in mammals and in the differentiation of intestinal epithelial cells. The Cdx2 gene is expressed in all but the most distal portions of the intestinal tract during development (1, 2) . In a cell culture model, Cdx2 has been shown to decrease cellular replication and induce differentiation to mature intestinal epithelium (3) . Cdx2 acts as a transcription factor, increasing the expression of several gene products associated with mature intestinal epithelial cells (3, 4) . Perhaps not surprisingly, Cdx2 has recently been identified as a gene whose expression had a high predictive value for the diagnosis of colonic adenocarcinoma in microarray gene expression analyses (5, 6) . The use of Cdx2 as an immunohistochemical marker has been described recently in studies of human gastric and colon cancer, but no comprehensive survey of Cdx2 protein expression has been reported (7) (8) (9) . To follow up on previous RNA transcript profiling data, we report our findings using immunohistochemistry on tissue microarrays to comprehensively profile the protein expression of Cdx2 in a broad range of human carcinomas and normal tissues.
MATERIALS AND METHODS

Tissue Specimens
Formalin-fixed, paraffin-embedded tissue blocks were obtained from the archives of the Department of Pathology of the University of Virginia Health System with institutional review board approval.
Tissue Microarrays
Targeted tissue areas were marked on H&E-stained sections corresponding to the paraffin blocks. One to three 0.6-mm tissue cores from each case were removed using a manual microarray device (Beecher Instruments, Silver Spring, MD) and inserted into recipient paraffin blocks. The tissue microarrays were sectioned at a 4-m thickness and placed on charged slides.
Immunohistochemistry
Tissue microarray and standard tissue histologic sections were deparaffinized, rehydrated, and blocked with methanolic 3% hydrogen peroxide. The slides were immersed in 10 mM citrate buffer, pH 6.0 and heated in a 1200W microwave oven at the highest power setting. Evaporated liquid was replenished at 5 minutes, then the slides were heated at high power for an additional 5 minutes. The slides were left in the buffer for an additional 10 minutes before being removed. The antibody used was a mouse monoclonal antibody raised against full-length recombinant Cdx2 protein (AM392-5 M; BioGenex, San Ramon, CA). Immunostaining was performed by hand using the prediluted antibody solution and a 30-minute incubation. After washing, antibody binding was visualized using the avidin-biotin-peroxidase technique (Vectastain Elite ABC kit, Vector Laboratories, Burlington, VT), followed by incubation with 3,3'-diaminobenzidine tetrahydrochloride. The slides were counterstained with hematoxylin.
The immunohistochemical stains were evaluated by two pathologists (HFF and CAM). Only nuclear staining was considered positive, and it was scored on the following basis: 0 (no detectable staining); 1ϩ (Ͻ25% positive cells); 2ϩ (25-49%); 3ϩ (50 -74%); 4ϩ (Ͼ75%). In general, cases showing 3ϩ and 4ϩ staining also had strong intense staining, so intensity was not factored into the scoring.
The list of normal tissues examined is given in Table 1 . Focal heterogeneous Cdx2 expression was present in the pancreatic tissue microarray samples, and standard histologic sections of this organ were also examined for confirmation of this finding.
The list of tumors examined is given in Table 2 . The following tumors were absent from or not well represented in the arrays, and additional cases were obtained and examined as standard histologic sections: germ cell tumors (12 additional cases), ampullary carcinoma (6 cases), and neuroendocrine carcinomas of the gastrointestinal tract, biliary tract, lung, and pancreas (30 cases).
RNA Gene Expression Profiling
Gene expression profiles of a subset of tumor cases were obtained on U95a GeneChips (Affymetrix, Santa Clara, CA), as reported previously (6) .
RESULTS
The degree of Cdx2 protein expression, as determined by immunohistochemistry, was compared with the level of Cdx2 RNA transcript levels for a subset of tumors. Transcript levels determined by hybridization to GeneChip oligonucleotide arrays (Affymetrix Inc.) were available for 20 breast adenocarcinomas, 19 colon adenocarcinomas, 2 gastric adenocarcinomas, 12 lung adenocarcinomas, 12 scoring, the hybridization intensity of Cdx2 on the GeneChips, which represents the range of RNA transcript levels, was scaled into quartiles. In general, there was good agreement between the average immunohistochemical score and the average transcript score for the subgroups of cancers (Fig.  1) . Table 1 shows the immunohistochemical results for the panel of normal tissues examined. Strong, diffuse Cdx2 staining was seen in intestinal epithelium, including tissue from the duodenum, ileum, appendix, colon, and rectum. The epithelium of major pancreatic ducts showed focal patchy staining, whereas centroacinar cells and the epithelium of pancreatic interacinar ductules and small pancreatic ducts showed strong diffuse staining. Pancreatic acinar epithelium and islet cells did not stain for Cdx2. No other normal tissue types had detectable Cdx2 staining. Figure 2 shows examples of Cdx2 immunohistochemistry in pancreas and other normal tissues. Although no typical ductal pancreatic adenocarcinoma showed Cdx2 staining, the single case of mucinous pancreatic adenocarcinoma showed strong diffuse immunoreactivity. Neuroendocrine tumors in general exhibited a pattern of Cdx2 staining that mirrored the anatomic distribution of Cdx2 expression in nonneuroendocrine carcinomas. Eight of 9 (89%) midgut and 4 of 9 (44%) hindgut carcinoids showed extensive Cdx2 expression, with carcinoids of the stomach, biliary tract, and lung showing no or only focal Cdx2 expression. The majority of pancreatic islet cell tumors also showed no or little staining for Cdx2, with only 1 of 14 cases (7.1%) showing Ͼ50% of cells staining.
DISCUSSION
Cdx2 is a gene essential for normal mammalian development. In adult animals, including humans, it is expressed in intestinal epithelial cells, where it acts as a transcription factor. Genes that are regulated by Cdx2, such as sucrase-isomaltase and lactase, are associated with the mature enterocyte phenotype, and the current paradigm is that Cdx2 is a master "control gene" for intestinal epithelial differentiation. Our data support the use of Cdx2 immunohistochemistry as a marker of intestinal cellular differentiation, even in the malignant state.
The highest frequency of extensive Cdx2 expression was seen in colorectal adenocarcinomas (90%). Ampullary and gastroesophageal adenocarcinomas, which often have histologic and histochemical evidence of intestinal differentiation, also had a substantial percentage of tumors with extensive Cdx2 expression (33 and 20%, respectively). Neuroendocrine tumors arising from various epithelia exhibit Cdx2 expression that mirrors that seen in the native non-neuroendocrine epithelia, with the highest frequency of extensive Cdx2 expression in the midgut (89%) and hindgut (44%). Interestingly, Cdx2 expression has been reported to be lower in the distal colorectum than in the rest of the gastrointestinal tract during development (2) , and the hindgut carcinoids in our collection were exclusively from the rectum. It is possible that the lower frequency of rectal carcinoids highly expressing Cdx2, when compared with the frequency of midgut carcinoids, is a reflection of this relative biological difference seen in the cell populations from which these tumors originate. The finding of high Cdx2 levels in neuroendocrine tumors derived from intestinal epithelium suggests that Cdx2 may also be playing a role in normal neuroendocrine cell differentiation, or that Cdx2 expression in gut epithelium does not alone determine differentiation to the absorptive cell phenotype.
When the Cdx2 gene is eliminated by one copy in mice, the animals develop hamartomatous polyps, in which it has been shown that the wild-type Cdx2 allele is not expressed. This observation has led to the screening of patients with intestinal hamartomatous polyposis syndromes for germline inactivating mutations of Cdx2; however, no such mutations have been identified (10) . In cell culture experiments, induced expression of Cdx2 has been shown to arrest proliferation in undifferentiated intestinal cells (3) . This observation, along with the heterozygous mouse model, suggests that Cdx2 may act as a tumor suppressor. However, in surveys of human colon carcinoma, except for a few rare tumors that also expressed high microsatellite instability (MI), gene mutation has not been found (10 -12) . Because Cdx 2 is neither mutated, nor is its gene expression lost in most cases of colorectal adenocarcinomas, it seems highly unlikely that it plays a role as a significant tumor suppressor. A subset of colon cancers described as "large cell minimally differentiated carcinomas" has been reported as lacking expression of Cdx2 (8) . These tumors also had a high incidence of MI, suggesting that both MI and Cdx2 loss are molecular alterations in colon cancer manifested by this large cell morphology. Because Cdx2 mutations occur in areas of repetitive DNA sequence within the gene (11) , it is likely that Cdx2 is not selected as a tumor suppressor gene when it is mutated in these can- cers but may be mutated as an "innocent bystander" as a consequence of the DNA mutator phenotype associated with MI. Once inactivated, however, it is also likely that the undifferentiated large cell phenotype is a consequence of Cdx2 mutation. This hypothesis is supported by studies with the IEC-6 cell line, a human colon cancer cell line that grows as undifferentiated tumors in nude mice. When Cdx2 expression is induced in these cells, the cells form tumors with glandular and villous structure, and ultrastructural features of both enterocytes and goblet cells are found (3) .
The data presented in this study show that strong, extensive nuclear Cdx2 immunohistochemical staining is very common in colorectal adenocarcinomas, with smaller numbers of adenocarcinomas of the stomach, esophagus, pancreas, ovary, and uterus showing this pattern. Of particular note is the differential expression of Cdx2 protein in mucinous tumors of the ovary as compared with adenocarcinomas arising in the colorectum. There often exists some uncertainty as to the primary site of origin of carcinomas in the ovary that show glandular or mucinous differentiation. The ovarian tumors used in this series were carefully screened to include only those cases with an adequate clinical examination to exclude a gastrointestinal primary tumor. Although not completely specific, the relatively low numbers of mucinous ovarian tumors showing extensive Cdx2 expression may make this a useful marker, perhaps as part of a panel of immunohistochemical stains, in separating metastatic gastrointestinal tumors from primary mucinous ovarian carcinomas. More definitive proof of the usefulness of this marker for this purpose will require a more focused study, with a larger number of cases.
Other potential uses of this marker include the workup of metastatic tumors at other sites. The marker may aid in the differential diagnosis of welldifferentiated neuroendocrine tumors first detected in the liver. Extensive positive Cdx2 staining predicts a metastasis from a gastrointestinal carcinoid of midgut or hindgut origin. Negative or focal Cdx2 staining predicts a source from the lung, stomach, biliary tract, or pancreas. As has been reported in abstract form by another group (13), our results suggest that Cdx2 immunohistochemistry is also useful in distinguishing primary lung adenocarcinomas from gastrointestinal metastases.
In conclusion, our immunohistochemical survey of Cdx2 protein expression is in excellent agreement with the results of global gene expression studies in which oligonucleotide microarrays were used. It is expected that the "mining" of such global gene expression surveys of human cancers will yield other candidate protein markers that can be assayed by immunohistochemistry to provide useful clinicopathologic information. 
